Details

Last Funding Type

Series C

Last Funding Money Raised

€50M

Industries

Biotechnology,Health Care,Medical,Personal Health,Pharmaceutical

Founded date

Jan 1, 2003

Number Of Employee

1 - 10

Operating Status

Active

Aprea is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB.